Infen-25

Pain of mild to moderate intensity eg, musculo-skeletal pain, dysmenorrhoea, dental pain.

25 mg every 8 hr. Total daily dose should not exceed 75 mg. Elderly Initiate at lower end of dose range (50 mg total daily dose). Patient w/ mild to moderate hepatic impairment or mild renal impairment Initiate at reduced doses (50 mg total daily dose).

Should be taken on an empty stomach: Take at least 30 min before meals.

Hypersensitivity to dexketoprofen or to any other NSAID. Patients in whom substances w/ a similar action (eg, aspirin, or other NSAIDs) precipitate attacks of asthma, bronchospasm, acute rhinitis, or cause nasal polyps, urticaria or angioneurotic oedema; w/ active or suspected GI ulcer or history of GI ulcer or chronic dyspepsia; who have GI bleeding or other active bleedings or bleeding disorders; w/ Crohn's disease or ulcerative colitis; history of bronchial asthma; severe heart failure; hemorrhagic diathesis & other coagulation disorders; moderate to severe renal impairment; severe hepatic impairment. 3rd trimester of pregnancy & lactation.

Not intended for long-term use; treatment must be limited to symptomatic period. Discontinue use at 1st appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity; or instances of GI bleeding or ulceration. Monitor for digestive disturbances, especially GI bleeding, in patients w/ GI symptoms or history of GI disease. Can inhibit platelet aggregation & prolong bleeding time; increase plasma urea nitrogen & creatinine; cause transient small increases in some liver parameters, & significant increases in SGOT & SGPT; mask symptoms of infectious diseases. Associated w/ adverse effects on renal system which can lead to glomerular nephritis, interstitial nephritis, renal papillary necrosis, nephrotic syndrome & acute renal failure. Discontinue therapy in case of relevant increase in liver parameters, SGOT & SGPT. Appropriate monitoring & advice are required for patients w/ history of HTN &/or mild to moderate CHF. May be associated w/ small increased risk of arterial thrombotic events (eg, MI or stroke) particularly at high doses & in long-term treatment. Caution in patients w/ history of allergic conditions; haematopoietic disorders, SLE or mixed connective tissue disease; hepatic, renal or cardiac impairment or other conditions predisposing to fluid retention; history of cardiac disease, particularly previous episodes of heart failure; uncontrolled HTN, CHF, established ischaemic heart disease, peripheral arterial disease, &/or cerebrovascular disease; risk factors for CV disease eg, HTN, hyperlipidaemia, DM, smoking. Not recommended in patients receiving other therapy that interferes w/ haemostasis eg, warfarin or other coumarins or heparins. May impair female fertility & is not recommended in women attempting to conceive. Consider w/drawal of treatment in women w/ difficulties conceiving or who are undergoing investigation of infertility. Not to be given during 1st & 2nd trimester of pregnancy unless clearly necessary. Safety & efficacy have not been established in childn & adolescents. Caution in the elderly.

Nausea &/or vomiting, abdominal pain, diarrhoea, dyspepsia.

Risk of GI ulcers & bleeding may be increased w/ other NSAIDs, including high doses of salicylates (≥3 g/day). Increased risk of haemorrhagic effect of oral anticoagulant. Increased risk of haemorrhage w/ heparins. Increased blood lithium levels. Increased haematological toxicity of MTX. May increase toxic effects of hydantoins & sulphonamides. May reduce effect of diuretics & antihypertensives. May result in further deterioration of renal function w/ ACE inhibitors or AIIA in some patients w/ compromised renal function eg, dehydrated patients or elderly w/ compromised renal function. Increased risk of bleeding w/ pentoxifylline; thrombolytics. Risk of increased red cell line toxicity w/ zidovudine. Increased hypoglycaemic effect of sulfonylureas. May decrease antihypertensive effect of β-blockers. May enhance nephrotoxicity w/ cyclosporin & tacrolimus. Plasma conc may be increased w/ probenecid. May increase plasma glycoside conc. May alter efficacy of mifepristone. Increased risk of developing convulsions w/ high doses of quinolones.

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

M01AE17 - dexketoprofen ; Belongs to the class of propionic acid derivatives of non-steroidal antiinflammatory and antirheumatic products.

Rx